Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone added to fluvoxamine for moderate-to-severe obsessive-compulsive disorder
IRCT20090117001556N169Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lurasidone and fluvoxamine in obsessive compulsive disorder (OCD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of obsessive-compulsive disorder. Started May 2026; status: completed.
02
Drugs
lurasidonefluvoxamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20090117001556N169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N169.